Company Filing History:
Years Active: 2013-2022
Title: Innovations by James Mignone: A Focus on Alpha V Integrin Inhibitors
Introduction
James Mignone is an accomplished inventor based in Hamilton, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target alpha V integrins. With a total of 4 patents to his name, Mignone's work is pivotal in addressing various medical conditions.
Latest Patents
Mignone's latest patents include innovative compounds such as substituted tetrahydropyrrolo[1,2-a]pyrazines and pyrrole amides, both of which serve as alpha V integrin inhibitors. The first patent focuses on compounds that inhibit α-containing integrins and includes pharmaceutical compositions for treating diseases associated with dysregulation of αV-containing integrins. These conditions include pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders. The second patent similarly provides compounds that inhibit α-containing integrins, offering methods for treating the same range of diseases and disorders.
Career Highlights
James Mignone is currently employed at Bristol-Myers Squibb Company, where he continues to innovate in the pharmaceutical sector. His work is characterized by a strong emphasis on developing effective treatments for serious health conditions.
Collaborations
Mignone collaborates with notable colleagues such as Guohua Zhao and William N. Washburn, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
James Mignone's contributions to the field of pharmaceuticals, particularly through his patents on alpha V integrin inhibitors, highlight his role as a key inventor in medical research. His work not only advances scientific knowledge but also has the potential to improve patient outcomes in various diseases.